United Therapeutics Corp’s recently made public that its PRESIDENT AND COO BENKOWITZ MICHAEL unloaded Company’s shares for reported $3.48 million on Feb 10 ’25. In the deal valued at $348.06 per share,10,000 shares were sold. As a result of this transaction, BENKOWITZ MICHAEL now holds 0 shares worth roughly $0.0.
Then, Michael Benkowitz bought 40,000 shares, generating $13,908,400 in total proceeds.
Before that, BENKOWITZ MICHAEL sold 10,000 shares. United Therapeutics Corp shares valued at $3,536,398 were divested by the PRESIDENT AND COO at a price of $353.64 per share. As a result of the transaction, BENKOWITZ MICHAEL now holds 0 shares, worth roughly $0.0.
Morgan Stanley downgraded its United Therapeutics Corp [UTHR] rating to an Equal-weight from a an Overweight in a research note published on July 11, 2024; the price target was increased to $321 from $310. A number of analysts have revised their coverage, including Goldman’s analysts, who increased its forecast for the stock in mid February from “a Sell” to “a Neutral”. Leerink Partners began covering UTHR with “an Outperform” recommendation on February 05, 2024. Wells Fargo started covering the stock on December 08, 2023. It rated UTHR as “an Overweight”.
Price Performance Review of UTHR
On Tuesday, United Therapeutics Corp [NASDAQ:UTHR] saw its stock jump 2.22% to $353.31. Over the last five days, the stock has lost -0.03%. United Therapeutics Corp shares have risen nearly 0.13% since the year began. Nevertheless, the stocks have risen 66.86% over the past one year. While a 52-week high of $417.82 was reached on 01/28/25, a 52-week low of $210.64 was recorded on 02/03/25. SMA at 50 days reached $363.02, while 200 days put it at $336.69.
Levels Of Support And Resistance For UTHR Stock
The 24-hour chart illustrates a support level at 345.53, which if violated will result in even more drops to 337.76. On the upside, there is a resistance level at 362.04. A further resistance level may holdings at 370.78. The Relative Strength Index (RSI) on the 14-day chart is 44.33, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -9.82, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 76.60%. Stochastics %K at 11.83% indicates the stock is a buying.
How much short interest is there in United Therapeutics Corp?
A steep rise in short interest was recorded in United Therapeutics Corp stocks on 2025-01-31, growing by 93125.0 shares to a total of 2.01 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-31 was 1.92 million shares. There was a rise of 4.62%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 06, 2022 when UBS began covering the stock and recommended ‘”a Buy”‘ rating along with a $320 price target.
